Drugs / H5 VLP vaccine
H5 VLP vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01991561 | Jun 2013 → Jul 2014 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00984945 Comparator | Sep → Dec 2009 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5 VLP vaccine | “We further report on safety and immunogenicity from a Phase I clinical study of the plant-made H5 VLP vaccine in healthy adults 18-60 years of age who received 2 doses 21 days...” PMID 21203523 ↗ Dec 2010 |
| Known as | H5 VLP pandemic influenza vaccine | “H5 VLP pandemic influenza vaccine 5 µg” NCT00984945 ↗ |
| Known as | plant-made H5 VLP vaccine | “We further report on safety and immunogenicity from a Phase I clinical study of the plant-made H5 VLP vaccine in healthy adults 18-60 years of age who received 2 doses 21 days...” PMID 21203523 ↗ Dec 2010 |
| Modality | Vaccine | “candidate Virus-Like Particle (VLP) vaccine” PMID 21203523 ↗ Dec 2010 |
| Route | Intramuscular | “0.5 mL, IM, 2 injections 21 days apart” NCT00984945 ↗ |